// App-Quantinova.ai

11504 : SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Researchers

Presenter

  • Sandra P. D'Angelo

Principal Investigators

  • Brian Andrew Van Tine

  • Steven Attia

  • Jean-Yves Blay

  • Sandra J. Strauss

  • Claudia Maria Valverde Morales

  • Albiruni Ryan Abdul Razak

  • Erin Van Winkle

  • Trupti Trivedi

  • Swethajit Biswas

  • Dennis Williams

  • Elliot Norry

  • Dejka M. Araujo

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Washington University School of Medicine, St. Louis, MO

  • Mayo Clinic, Jacksonville, FL

  • Centre Leon Berard, Lyon, France

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Canada.

  • Adaptimmune, Philadelphia, PA

  • Adaptimmune Ltd, Oxfordshire, United Kingdom

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • France

  • United Kingdom

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Synovial sarcoma

  • Liposarcomas

Biomarkers

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT04044768

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved